A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this study is to evaluate the long-term safety and tolerability of Xanomeline and Trospium Chloride for the treatment of psychiatric disorders in children and adolescents
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 400
- sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- conditions
- Schizophrenia; Autism-Related Irritability
- interventions
- DRUG: KarXT; DRUG: KarX-EC
- start date
- 2026-04-07
- start date type
- ACTUAL
- primary completion date
- 2030-03-08
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07424404
- Published
- Feb 20, 2026
- Updated
- Oct 15, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07424404
- Categories
- Schizophrenia, Autism-Related Irritability
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials